FDA
-
-
-
-
-
-
-
HCW Biologics begins first human trial of HCW9302 for autoimmune disease
-
-
-
-
-
-
-
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
-
-
-
-
-
-
-
HCW Biologics Announces 1-for-40 Reverse Stock Split
-
-
-
-
-
-
-
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
-
-
-
-
-
-
-
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
-
326,538 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

